fbpx
QQQ
+ 2.45
314.44
+ 0.77%
DIA
+ 4.04
332.15
+ 1.2%
SPY
+ 4.46
401.25
+ 1.1%
TLT
+ 0.21
135.39
+ 0.15%
GLD
+ 0.70
169.74
+ 0.41%

Cannabis Research Skyrocketed In 2020

January 6, 2021 12:29 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Research Skyrocketed In 2020

This article by Louis O'Neill was originally published on The Green Fund, and appears here with permission.

2020 saw over 3,500 research papers released that look into cannabis and its effects, making it a record year for the plant.

As we've discussed here many times at The Green Fund, research into cannabis remains one of the keys to pushing the industry toward the mainstream and into legalization.

As Australia's Therapeutic Goods Administration (TGA) outlined in 2019, "in many cases, there are very limited data from which to draw specific recommendations for treatment."

Given that cannabis remains a Schedule I substance in the U.S. due to its perceived "lack of accepted medical uses," one of the linchpins of widespread cannabis legalization is through a growing body of research surrounding the medical uses of cannabis and its derivatives.

Thankfully, it appears the tides are turning, and cannabis is finally getting the attention it deserves.

Throughout 2020, it was found that over 3,500 research papers on cannabis were published of cannabis, representing the most studies on the plant of any year in its history.

This news comes after a series of bills were introduced into the U.S. House of Representatives and Senate that seek to further accelerate studies into cannabis in the country.

Marijuana Research Studies 2020

The increased transparency and understanding of cannabis is undoubtedly a good thing, however, it's also important to remember that not every study into cannabis will yield desirable results.

In fact, it was found last year that of the $1.56 billion that has been spent on cannabis research since 2000, roughly half of that money was spent on looking into the harms and dangers of cannabis use and abuse.

Moreover, the study found that the majority of the research funding came from the U.S. National Institute for Drug Abuse, which invested $1 billion into studying cannabis and its effects, predominantly through the lens of harmful effects of cannabis misuse and abuse.

Just as the Tobacco industry weaponized studies in the 1950s to create more favourable scientific studies, we may similarly see anti-drug lobbying organizations and large pharmaceutical companies using scientific studies to hinder progress on the disruptive potential of medical and recreational cannabis.

Studying cannabis will be crucial in getting cannabis removed from its strict scheduling under U.S. law, but cannabis advocates should be aware of potential efforts to subvert research against the industry.

Read the original Article on The Green Fund.

Benzinga's Related Links: 


Related Articles

Cannabis Movers & Shakers: Willow Biosciences, Civilized, Veritas Farms, Item 9, LeafLine Industries

Willow Biosciences Names Barbara Munroe Board Member Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) has appointed Barbara Munroe to its board of directors. read more

4Front Mission And Homegrown Detroit Offer Cannabis Grow Workshop to Legacy Detroiters May 16

4Front Ventures Corp.'s (CSE: FFNT) (OTCQX: FFNTF) cannabis brand Mission Dispensaries has teamed up with Homegrown Detroit to promote equitable access to the cannabis industry. read more

Project Twenty 21 Releases Findings: Cannabis Dramatically Improves Lives Of Patients With Debilitating Conditions

Project Twenty 21 has published its first findings in the accredited scientific journal Psychopharmacology. The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London. read more

Cannabis Movers & Shakers: Valens, Ayurcann, SpeakEasy, General Cannabis

Valens Shakes Up Leadership Team The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) has recently appointed Sunil Gandhi as its chief financial officer and Adam Shea as chief commercial officer. read more